170 results about "Antiantibody" patented technology

Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

Methods of therapy for treating a subject for multiple myeloma are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-antibody or antigen-binding fragment thereof beneficially inhibits proliferation and / or differentiation of human CD40 expressing multiple myeloma cells.

The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.

Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and / or LukB, or anti-LukA and / or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.

The invention relates to an anti-H7N9 all-human-derived monoclonal antibody 2J17, and a preparation method and application thereof. The heavy chain variable region amino acid sequence of the antibody is disclosed as SEQ ID NO:2, or an amino acid sequence with the same function, which is formed by performing substitution, deletion or addition of one or more amino acids on the sequence; and / or the light chain variable region amino acid sequence of the antibody is disclosed as SEQ ID NO:4, or an amino acid sequence with the same function, which is formed by performing substitution, deletion or addition of one or more amino acids on the sequence. The antibody 2J17 can be bound with hemagglutinin HA of the H7N9 virus in a targeted way. Compared with the rat-derived antibody, genes of the all-human-derived antibody are completely derived from human genes without components of other species, so that the all-human-derived antibody does not have rat antiantibody resistance and other toxic or side effects in the human body, has better biocompatibility, and has higher adaptability and potential to become the macromolecular drug for treating influenza viruses.

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

The present application is in the field of sialic acid chemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc) in bio-logical materials, such as food and clinical specimens. Such detection and analysis is facilitated by the use of Neu5Gc specific antibodies. The present invention also relates to the detection of anti Neu5Gc antibodies in clinical samples, as well as the production of anti-Neu5Gc specific antibodies.

The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.

The invention discloses a method for detecting illegal cooking oil, test paper and application of the test paper. According to the method, a lipopolysaccharide antibody and / or a fat-soluble protein antibody are / is taken as an antibody for detection. The method comprises the following steps of: preparing an antibody A and an antibody B by using a hybridoma cell strain gzcdc-ETX001; reacting fluorescein molecules with glucan molecules to obtain glucan molecules combined with fluorescein, reacting the glucan molecules combined with the fluorescein with the antibody B, and purifying to obtain a glucan-antibody B-fluorescein mixed marker; and reacting a sample to be tested with the antibody A, adding the glucan-antibody B-fluorescein mixed marker, continuing to react, and detecting by using a device for detecting fluorescence so as to judge whether the illegal cooking oil is contained in the sample to be tested. The glucan-antibody B-fluorescein mixed marker is enveloped by a bonding pad in the test paper for implementing the method; and a detection band on a chromatographic membrane is fixed with the antibody A, and a quality control band is fixed with an antiantibody which can be specifically combined with the glucan-fluorescein marked antibody B. The test paper is sensitive and easy to use.

The invention discloses a kit and method for detecting Tilletia controversa Kuhn and belongs to the technical field of plant pathogen detection. The kit comprises a test paper strip and a micropore plate. The test paper strip comprises a base plate, a sample absorption pad, a reaction membrane and a water absorption pad. The sample absorption pad, the reaction membrane and the water absorption pad are orderly pasted to the base plate. The kit is characterized in that a freeze-dried micropore reagent is arranged in micropores of the micropore plate, the micropore reagent is a gold-labeled antibody obtained by labeling of a monoclonal antibody shown in the claim 2 with colloidal gold, the reaction membrane is divided into a detection zone and a quality control zone, the detection zone is coated with polyclonal antibodies of Tilletia controversa Kuhn, and the quality control zone is coated with antiantibodies. The kit has good singularity and a very low detection limit and is suitable for prevention and control or quarantine inspection of Tilletia controversa Kuhn.

The invention relates to a test reagent box of multiple antigen membrane method which is used for diagnosing RA, it includes tablets and response groove, the tablets hold on the response groove; the tablets gap corresponding to the response groove gap; there is multi-personal reaction zone on the tablets which correspond with the multi-groove of reaction groove, there is a gap on the top of each groove; membrane bar test paper adhere to each reaction zone and with RA correlate antigen and response control belt; the RA related antigen is the corresponding antigen of RF, anti-CCP, anti-RA-33 antibody, anti-Sa antibody, anti-P68 or more than four kinds of antigen in antigen epitope polypeptide or antigen epitope polypeptide, the response control belt is a mixture of man IgG and man IgM. The reagent box in this invention overcome the lack of detection sensitivity and Specificity of the single autoantibody and the red tape of several autoantibody detection in a single operation, it provide the accuracy and convenience of RA diagnosis. The invention also disclosed the method of how to make the test box.

The present application is in the field of sialic acid chemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc) in bio-logical materials, such as food and clinical specimens. Such detection and analysis is facilitated by the use of Neu5Gc specific antibodies. The present invention also relates to the detection of anti Neu5Gc antibodies in clinical samples, as well as the production of anti-Neu5Gc specific antibodies.

The present invention discloses a method for detecting evermection and its special-purpose ELIA kit. Said kit includes evermectin specific antibody, coating source and enzyme label. The described coating source is conjugate of evermectin semiantigen and carrier protein or antiantibody; the described enzyme label is enzyme-labelled antiantibody or enzyme-labelled evermectin semiantigen. When the described coating source is the conjugate of evermectin semiantigen and carrier protein, the described enzyme label is enzyme-labelled antiantibody, and when the described coating source is antiantibody, the described enzyme label is enzyme-labelled evermectin semiantigen.

The invention discloses a method for joint detection of PCT, CRP and IL-6 and a reagent kit for the method. The reagent kit comprises a first enveloping film and a second enveloping film. One end of the first enveloping film is connected with one end of the second enveloping film, and a labeled antibody mixture is enveloped in at least one area in the first enveloping film and comprises a first labeled antibody, a second labeled antibody and a third labeled antibody. The second enveloping film comprises a first area, a second area, a third area and a fourth area which are separated, wherein a first enveloped antibody, a second enveloped antibody and a third enveloped antibody are enveloped in the first area, the second area and the third area respectively, the first enveloped antibody and the first labeled antibody can be in specific binding with a first antigen, the second enveloped antibody and the second labeled antibody can be in specific binding with a second antigen, the third enveloped antibody and the third labeled antibody can be in specific binding with a third antigen, an antiantibody is enveloped in the fourth area, and the antiantibody can be in specific binding with the first labeled antibody, the second labeled antibody and the third labeled antibody. By means of the reagent kit, PCT, CRP and IL-6 can be quickly and accurately detected at the same time.

The invention discloses an immunochromatographic test strip for detecting MG and a preparation process thereof. The immunochromatographic test strip for detecting MG provided in the invention comprises a sample pad containing MG antibodies marked by superparamagnetic composite particles, a cellulose nitrate membrane connected with one end of the sample pad and an absorbent connected with another end of the cellulose nitrate membrane; the cellulose nitrate membrane is coated by mutually separated detection lines and quality control lines, wherein, the detection lines contain MG antigens, and the quality control lines contain antiantibodies which can specifically bind to the MG antibodies. Experiments in the invention prove that the test strip provided in the invention has the advantages of high sensitivity, strong specificity, rapidness, simpleness and capability of realizing objective detection when is used for detecting MG.

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody.

The present invention discloses a method for detecting 19-nandrolone and its special-purpose ELIA kit. Said kit includes 19-nandrolone specific antibody, coating source and enzyme label. The described coating source is conjugate of 19-nandrolone semiantigen and carrier protein or antiantibody. The described enzyme label is enzyme-labelled antiantibody or enzyme-labelled 19-nandrolone semiantigen. When the described coating source in the conjugate of 19-nandrolone semiantigen and carrier protein, the described enzyme label is enzyme-labelled antiantibody, and when the described coating source is anti-antibody, the described enzyme label is the enzyme-labelled 19-nandrolone semi-antigen.

The present invention relates reagent kit for IgG immunoblotting diagnosis of SARS coronavirus antibody. The reagent kit consists of solid film, antiantibody of enzyme label and corresponding chromogenic substrate. The solid film is obtained through purifying SARS coronary totivirus lysate liquid antibody or recombining mixed antigen, gel electrophoresis to separate and transferring to film. The antiantibody of enzyme label is compounded with rabbet's antihuman IgG labeled with horseradish peroxidase or sheep's antihuman IgG labeled with alkaline phosphatase, 0.01 % concentration thimerosal as protecting agent, ox serum protein in 1 wt% and PBS in pH 7.4 in 0.01 M. The present invention may be used in detecting several kinds of antigen and antibody in clinical test department and sanitary epidemic prevention department.

The invention provides an enzyme linked immune regent box to detect gentamycin. It includes: the enzyme labeled board which encrusts the encrusting substance, the enzyme marker, the special antibody for the gentamycin (when the antigen is on enzyme labeled board and the enzyme marker is the enzyme labeled antiantibody or the antiantibody is in the enzyme labeled board and the enzyme marker is the enzyme labeled antigen), the gentamycin standard solution, the substrate color solution, the stop solution, the condense washing solution, the condense recovery solution. The invention also discloses the method which includes the process: first to pre-treat the sample, then to detect by the regent box and last to analyze the detecting result. The invention is to detect the gentamycin residue weight in the animal food such as the chicken, chicken liver, pork, pork liver, milk powder, egg and feedstuff. The method is simple, low cost and has high sensitivity, also it is proper for detect the mass sample.

The invention discloses test paper and a method for detecting florfenicol and thiamphenicol. The test paper comprises a micropore reagent and a test strip, the micropore reagent comprises freeze-dried colloidal-gold-labelled thiamphenicol medicament specific antibody, wherein the thiamphenicol medicament specific antibody is thiamphenicol medicament monoclonal antibody or thiamphenicol medicament polyclonal antibody; the test strip is formed by successively connecting a sample absorption pad, a reaction membrane, a water absorption pad, a protective membrane and a base plate, the reaction membrane comprises a detection zone and a quality control zone, the detection zone is coated with thiamphenicol hapten-carrier protein conjugate, and the quality control zone is coated with antiantibody. The method for detecting florfenicol and thiamphenicol by using the test paper provided by the invention is simple, rapid, visualized, accurate, wide in application scope, low in cost and easy to popularize and use.

Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.

Antibodies to FcRn are provided which are non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal or monoclonal or antigen binding fragment thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.

The invention provides an enzyme linked immunosorbent assay kit for detecting zearalenone drugs and an application thereof; the kit comprises an enzyme label plate coated with a coating antigen, an enzyme label, a zearalenone specific antibody working fluid (which is included when the enzyme label plate is coated with the coating antigen and the enzyme label is an enzyme labeled antiantibody, or when the enzyme label plate is coated with an antiantibody and the enzyme label is an enzyme labeled antigen), a zearalenone standard substance solution, a substrate developing solution, a stopping solution, and a concentrated washing liquid. Detection of zearalenone with the kit of the invention comprises the following steps: firstly pretreating a sample, then detecting with the kit, and finally analyzing the detection result. The enzyme linked immunosorbent assay kit provided by the invention can be used for detection of the residual amount of zearalenone in a feed sample, which is simple in operation, low in price, high in sensitivity, suitable for on-site monitoring, and suitable for screening of a large number of samples.